Algorx Pharmaceuticals Inc (NASDAQ:AGRX) Quarterly Sentiment Report

December 8, 2017 - By Hazel Jackson

 Algorx Pharmaceuticals Inc (NASDAQ:AGRX) Quarterly Sentiment Report

Sentiment for Algorx Pharmaceuticals Inc (NASDAQ:AGRX)

Algorx Pharmaceuticals Inc (NASDAQ:AGRX) institutional sentiment decreased to 0.61 in 2017 Q2. Its down -0.39, from 1 in 2017Q1. The ratio worsened, as 19 institutional investors started new and increased holdings, while 31 cut down and sold equity positions in Algorx Pharmaceuticals Inc. The institutional investors in our partner’s database reported: 21.56 million shares, up from 21.41 million shares in 2017Q1. Also, the number of institutional investors holding Algorx Pharmaceuticals Inc in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 15 Reduced: 16 Increased: 7 New Position: 12.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $162.04 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

The stock increased 3.95% or $0.18 during the last trading session, reaching $4.74. About 260,771 shares traded or 14.75% up from the average. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since December 8, 2016 and is downtrending. It has underperformed by 65.41% the S&P500.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on March, 14. They expect $-0.26 earnings per share, up 10.34 % or $0.03 from last year’s $-0.29 per share. After $-0.22 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 18.18 % negative EPS growth.

Proquest Associates Iv Llc holds 24.27% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Caxton Corp owns 1.62 million shares or 9.5% of their US portfolio. Moreover, Aisling Capital Llc has 1.16% invested in the company for 1.80 million shares. The Sweden-based Investor Ab has invested 0.92% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 1.25 million shares.#img1#

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 4 Wall Street analysts rating Agile Therapeutics, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8.0 while the high is $16. The stock’s average target of $10.50 is 121.52% above today’s ($4.74) share price. AGRX was included in 15 notes of analysts from December 30, 2015. As per Friday, July 14, the company rating was maintained by RBC Capital Markets. The firm earned “Buy” rating on Friday, July 28 by H.C. Wainwright. H.C. Wainwright maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Thursday, October 12 with “Buy” rating. Cantor Fitzgerald initiated the stock with “Buy” rating in Friday, January 8 report. The stock has “Buy” rating by Noble Financial on Friday, July 28. On Monday, October 2 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The firm has “Buy” rating given on Monday, June 12 by Noble Financial. The rating was initiated by Noble Financial with “Buy” on Wednesday, December 30. The firm has “Buy” rating given on Thursday, November 9 by Noble Financial. The firm has “Buy” rating given on Monday, November 20 by Cantor Fitzgerald.

More notable recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: Seekingalpha.com which released: “Agile Therapeutics: Is This ~$3.50 ‘Busted IPO’ Worthy Of Investment …” on September 05, 2017, also Globenewswire.com with their article: “Agile Therapeutics to Present Additional Phase 3 Data at the North American …” published on September 28, 2017, Thestreet.com published: “How a Birth Control Patch Hurt Agile Therapeutics’ Stock” on January 04, 2017. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) were released by: Globenewswire.com and their article: “Agile Therapeutics Reports Third Quarter 2017 Financial Results” published on November 06, 2017 as well as Globenewswire.com‘s news article titled: “Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual …” with publication date: September 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.